Authors
Claire White
Published in
Clinical journal of oncology nursing. Volume 30. Pages E84-E87. Jul 08, 2026.
Abstract
Genetically modified cellular therapies (GMCTs) are increasingly used to treat imminently life-threatening illnesses. However, these therapies are associated with substantial costs, require specialized care, and are available at only a limited number of treatment centers, creating significant barriers to patient access and healthcare delivery.
The aim of this article is to examine the logistic and financial clearance challenges associated with GMCTs and to highlight the role of nurses in facilitating timely patient access and sustainable therapy delivery.
A descriptive overview was conducted of the financial and operational considerations involved in the administration of GMCTs, with a focus on reimbursement processes, access barriers, and nursing contributions to financial clearance workflows.
The high cost, specialized care requirements, and limited availability of GMCTs create complex logistic and reimbursement challenges that can delay treatment access and threaten the sustainability of therapy delivery. Nurses play a critical role in supporting financial clearance processes, helping to streamline access pathways and optimal reimbursement outcomes for patients receiving cell and gene therapies.
PMID:
42462104
Bibliographic data and abstract were imported from PubMed on 17 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0